Myelodysplastic Syndromes Pipeline

Myelodysplastic Syndrome Pipeline report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Myelodysplastic Syndrome market. A detailed picture of the Myelodysplastic Syndrome pipeline landscape is provided, which includes the disease overview and Myelodysplastic Syndrome treatment guidelines.

Some of the key highlights of the Myelodysplastic Syndromes Pipeline Report

  • Luspatercept(NCT04064060) is an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
  • Myelodysplastic syndromes into subtypes based on the type of blood cells — red cells, white cells, and platelets.
  • Key players involved in the Celgene Corporation, Keros Therapeutics, Otsuka Pharmaceutical Co. Ltd, Horizon Pharma USA, Inc., and many others
  • Myelodysplastic Syndromes Pipeline therapies involved Luspatercept, KER-050, ASTX030, IFN-γ (interferon gamma-1b) injection, and many others

Request for Sample @ Myelodysplastic Syndromes Pipeline Insights

Myelodysplastic Syndromes Overview

Myelodysplastic syndrome (MDS) constitutes a group of clonal myeloid neoplasms characterized by anemia or other cytopenias due to ineffective hematopoiesis, abnormal blood, and bone marrow cell morphology, as well as, the risk for clonal evolution and progression to acute myeloid leukemia (AML).

Myelodysplastic Syndromes Therapy: Drug Profile

NCT04064060: Celgene Corporation

Celgene Corporation initiated a Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept. Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain.

Know More Information @ Myelodysplastic Syndromes Pipeline Drugs

Key Pipeline Therapies along with companies

  • Luspatercept: Celgene Corporation
  • KER-050: Keros Therapeutics
  • ASTX030: Otsuka Pharmaceutical Co., Ltd.
  • IFN-γ (interferon gamma-1b) injection: Horizon Pharma USA, Inc.

Myelodysplastic Syndromes Therapeutics Assessment

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Intravenous
  • Inhalation
  • Oral
  • Subcutaneous 

By Molecule Type 

  • Small Molecule 
  • Gene Therapy
  • Stem Cell Therapy

By Mechanism of Action

  • Protease Inhibitors
  • Immunomodulatory

By Targets

  • Protease 
  • Immune System

Contact here for more information @ Myelodysplastic Syndromes Pipeline Assessment 

Scope of Myelodysplastic Syndromes Pipeline Report

  • Coverage- Global
  • Major companies involved in the Myelodysplastic Syndromes pipeline report like as Celgene Corporation, Keros Therapeutics, Otsuka Pharmaceutical Co. Ltd, Horizon Pharma USA, Inc., and many others
  • Myelodysplastic Syndromes Pipeline therapies involved Luspatercept, KER-050, ASTX030, IFN-γ (interferon gamma-1b) injection, and many others

Following is the Table of Content of the Myelodysplastic Syndromes Pipeline Report

1 Report Introduction
2 Myelodysplastic Syndrome 
3 Myelodysplastic Syndrome Current Treatment Patterns
4 Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective
5 Therapeutic Assessment
6 Myelodysplastic Syndrome Late Stage Products (Phase-III)
7 Myelodysplastic Syndrome Mid Stage Products (Phase-II)
8 Early Stage Products (Phase-I)
9 Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 Myelodysplastic Syndrome Discontinued Products
13 Myelodysplastic Syndrome Product Profiles
14 Myelodysplastic Syndrome Key Companies
15 Myelodysplastic Syndrome Key Products
16 Dormant and Discontinued Products
17 Myelodysplastic Syndrome Unmet Needs
18 Myelodysplastic Syndrome Future Perspectives
19 Myelodysplastic Syndrome Analyst Review
20 Appendix
21 Report Methodology

Know more of what’s covered in the Myelodysplastic Syndrome Pipeline Assessment report

Key Questions Answered in the Myelodysplastic Syndrome report

  • What are the current options for Myelodysplastic Syndrome treatment?
  • How many companies are developing therapies for the treatment of Myelodysplastic Syndrome? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Myelodysplastic Syndrome?
  • How many Myelodysplastic Syndrome emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Myelodysplastic Syndrome?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Myelodysplastic Syndrome market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Myelodysplastic Syndrome?  
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Myelodysplastic Syndrome therapies? 
  • What are the clinical studies going on for Myelodysplastic Syndrome and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Myelodysplastic Syndrome? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Myelodysplastic Syndrome? 

Request for demo @ Myelodysplastic Syndrome Pipeline and get a walk-through of our report

Related Reports

Bladder cancer Market

DelveInsight’ s Bladder cancer – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

ER+/ HER2 -ve Breast Cancer Market

DelveInsight’s ER+/ HER2 -ve Breast Cancer – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of history.

Colorectal Cancer Market

DelveInsight’ s Colorectal Cancer (CRC) – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of history.

Melanoma Market

DelveInsight’ s Melanoma – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Visit on our blog section- 

About DelveInsight

DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.

See Campaign: https://www.delveinsight.com/
Contact Information:
Shruti Thakur info@delveinsight.com

Tags:
PR-Wirein, IPS, Reportedtimes, Menafn, iCN Internal Distribution, Extended Distribution, Research Newswire, English

Contact Information:

Shruti Thakur
info@delveinsight.com